Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Grifols SA ( (GRFS) ) has shared an update.
On April 14, 2026, Grifols S.A. announced it had successfully refinanced its 2027 debt maturities through a new Term Loan B credit agreement, split into a USD 2 billion U.S. dollar term loan, a EUR 1.25 billion euro term loan, and a USD 2.065 billion revolving credit facility. The term loans carry seven-year maturities, the revolving facility six and a half years, with pricing tied to SOFR and Euribor plus margins that step down as leverage improves.
The company will use the proceeds to fully repay its existing 2019 Term Loan B facilities, redeem the remaining 2019 notes, and bolster liquidity, thereby simplifying and extending its debt maturity profile. Together with the previously announced redemption of EUR 500 million of April 2024 notes, the refinancing is set to reduce funded gross debt, lower cash interest costs, and strengthen Grifols’ balance sheet while preserving strong liquidity for future development.
The most recent analyst rating on (GRFS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.
Spark’s Take on GRFS Stock
According to Spark, TipRanks’ AI Analyst, GRFS is a Neutral.
The score is held back primarily by weak technicals (price below key moving averages with negative momentum) and balance-sheet risk from elevated leverage. These are partially offset by improving profitability/cash generation that supports deleveraging and a moderate valuation with a small dividend yield.
To see Spark’s full report on GRFS stock, click here.
More about Grifols SA
Grifols S.A. is a Spanish healthcare company based in Barcelona, operating in the global biopharmaceutical and plasma-derived medicines industry. The group focuses on developing and supplying plasma therapies and related healthcare services, with a significant international footprint and access to U.S. and European credit markets to support its capital-intensive operations.
Average Trading Volume: 666,801
Technical Sentiment Signal: Sell
Current Market Cap: $6.55B
For a thorough assessment of GRFS stock, go to TipRanks’ Stock Analysis page.